China Biotechs Race To Get First Global IO Green Light Within Months
Multiple US Fast-Track Reviews Underway
Within months, one of the three latest immuno-oncology drugs from Chinese firms Innovent, Junshi and Akeso is likely to be approved, providing new competition to global giants such as BMS and Merck & Co. as they race each other over to the finish line.
